<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology of tuberculosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology of tuberculosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology of tuberculosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Robert Horsburgh Jr, MD, MUS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An understanding of the epidemiology of <em>Mycobacterium tuberculosis</em> is critical for effective control. The global burden of tuberculosis (TB), risk factors for transmission, and the epidemiology of TB in the United States will be reviewed here. The epidemiology of drug-resistant TB is discussed separately. (See  <a class="medical medical_review" href="/d/html/8027.html" rel="external">"Epidemiology and molecular mechanisms of drug-resistant tuberculosis"</a>.)</p><p class="headingAnchor" id="H6462182"><span class="h1">M. TUBERCULOSIS COMPLEX</span><span class="headingEndMark"> — </span><em>M. tuberculosis</em> is a member of the <em>M. tuberculosis</em> complex; other members include <em>Mycobacterium africanum</em> and <em>Mycobacterium bovis</em>.</p><p><em>M. africanum</em> is most commonly found in West African countries; it causes up to a quarter of cases of TB in the Gambia [<a href="#rid1">1</a>]. The symptoms of infection resemble those of <em>M. tuberculosis</em>. The infectivity is similar to <em>M. tuberculosis</em>, and it is an important opportunistic pathogen in the setting of advanced immunosuppression due to human immunodeficiency virus (HIV) or other causes. Management is identical to management for disease due to <em>M. tuberculosis</em>.</p><p><em>M. bovis</em> is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8006.html" rel="external">"Mycobacterium bovis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GLOBAL BURDEN</span></p><p class="headingAnchor" id="H1743440073"><span class="h2">Epidemiology and socioeconomic factors</span><span class="headingEndMark"> — </span>More than 1.7 billion people (approximately 22 percent of the world population) are estimated to be infected with <em>M. tuberculosis</em> [<a href="#rid2">2,3</a>]. The global incidence of TB peaked around 2003 and appears to be declining slowly [<a href="#rid3">3</a>]. According to the World Health Organization (WHO), in 2021, 10.6 million individuals became ill with TB and 1.6 million died [<a href="#rid4">4</a>].</p><p>The epidemiology of TB varies substantially around the world  (<a class="graphic graphic_figure graphicRef55097" href="/d/graphic/55097.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef111123" href="/d/graphic/111123.html" rel="external">table 1</a>). The highest rates (300 per 100,000 or higher) are observed in sub-Saharan Africa, India, and the islands of Southeast Asia and Micronesia. Intermediate rates of TB (26 to 300 cases per 100,000) occur in China, Central and South America, Eastern Europe, and northern Africa. Low rates (less than 25 cases per 100,000 inhabitants) occur in the United States, Western Europe, Canada, Japan, and Australia.</p><p>Poverty, HIV, and drug resistance are major contributors to the resurging global TB epidemic [<a href="#rid5">5,6</a>]. Approximately 95 percent of TB cases occur in resource-limited countries. Approximately 1 in 12 new TB cases occur in individuals who are infected with HIV; 74 percent of these HIV-coinfected persons resided in Africa [<a href="#rid3">3</a>]. An estimated 465,000 cases of multidrug-resistant (MDR-) TB or rifampin-resistant TB also occurred in 2019.</p><p>Socioeconomic development and access to quality of health services appear to be at least as important as any specific TB control measure. The likelihood of success of TB control efforts is likely related to socioeconomic indicators, including gross domestic product per capita, mortality of children &lt;5, access to clean water, and adequate sanitation and health expenditure per capita [<a href="#rid7">7</a>]. </p><p>The importance of addressing these socioeconomic factors to achieve TB control is reinforced by the fact that many countries have experienced a rapid decline in TB burden without good access to high-quality TB treatment. In Europe, for example, TB morbidity and mortality declined long before effective chemotherapy was available, largely because of socioeconomic development, improved living conditions, better nutrition, and isolation of infectious cases in sanatoria [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H3601360805"><span class="h2">Approach to global elimination</span></p><p class="headingAnchor" id="H160059122"><span class="h3">WHO "End TB" strategy</span><span class="headingEndMark"> — </span>The WHO’s "End TB" strategy for 2016 to 2035 focuses on reducing deaths, reducing disease incidence, and reducing catastrophic costs due to TB  (<a class="graphic graphic_table graphicRef99089" href="/d/graphic/99089.html" rel="external">table 2</a>). These TB goals were established as part of the Sustainable Development Goals (SDG) for 2016 to 2030 [<a href="#rid9">9</a>]. </p><p>The new goals include a 90 percent reduction in TB deaths and an 80 percent reduction in TB incidence rate by 2030. Accomplishing these goals will require accelerating the decline in TB incidence from the current rate (1.5 to 2 percent) to 15 percent annually; such a decline could reduce the incidence of TB to &lt;1 case per million by 2050. Achievement of this goal requires improvements in diagnosis, completion of disease treatment, and latent infection diagnosis and treatment. </p><p>The 2016 to 2035 SDGs for TB also recognize that TB treatment forces many patients and their families into poverty; thus, an additional important goal is that "no affected families face catastrophic costs related to TB."</p><p>Reasonable progress was made towards these goals in 2018 and 2019, but the coronavirus disease pandemic in 2019 and 2020 disrupted progress and will likely have a long-term negative impact [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H1898240431"><span class="h3">Active case finding</span><span class="headingEndMark"> — </span>The greatest barrier to reducing TB incidence and TB deaths is the substantial proportion of persons with TB disease that are never diagnosed and thus never treated. The WHO estimates that roughly 30 percent of such persons are never diagnosed [<a href="#rid3">3</a>]. Thus, efficient strategies for screening and treating these individuals, known as "active case finding," are needed. </p><p>Such programs need to screen for TB disease among patients not seeking health care for symptoms; approaches have included radiographic screening, sputum screening, and symptom surveys [<a href="#rid11">11,12</a>]. Interventions have targeted populations at increased risk including known contacts of individuals with active TB as well as individuals who are homeless, incarcerated, and/or HIV-infected. </p><p>The optimal approach to finding individuals with undiagnosed TB disease in high-incidence regions is uncertain; most cases occur in the absence of recognized risk factors [<a href="#rid13">13</a>]. In a cluster-randomized trial in Vietnam, active community-wide screening was compared with standard passive case detection (control) for reducing the prevalence of pulmonary TB among individuals ≥15 years, regardless of symptoms [<a href="#rid14">14</a>]. In 60 intervention clusters, active screening via sputum nucleic acid amplification testing (NAAT) was performed annually for three years, and antituberculous therapy was administered to patients diagnosed with TB; in 60 control clusters, no active screening was performed. In the fourth year, the prevalence of pulmonary TB was assessed via sputum NAAT (42,150 participants in the intervention group and 41,680 participants in the control group); active screening was associated with a lower prevalence of pulmonary TB than standard passive case detection alone (126 versus 225 per 100,000; prevalence ratio 0.56, 95% CI 0.40-0.78). </p><p>Further investigation is needed prior to broad implementation of active screening to assess the generalizability of these findings, the durability of the effect in endemic settings, and the feasibility of scaling up screening with NAATs.</p><p class="headingAnchor" id="H1043485719"><span class="h3">LTBI screening and treatment</span><span class="headingEndMark"> — </span>Controlling the TB epidemic also requires programs addressing the large burden of latent TB infection (LTBI); the 2015 WHO guidelines on LTBI management outline a strategy for identification and treatment of individuals with LTBI at increased risk for progression from latent infection to active disease [<a href="#rid15">15</a>]. These guidelines are aimed largely at middle- and upper-income countries; they recommend focusing efforts on case contacts and individuals with HIV infection, patients initiating anti-tumor necrosis factor treatment, patients receiving dialysis, patients preparing for organ or hematologic transplantation, and patients with silicosis. (See  <a class="medical medical_review" href="/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Progress toward targets</span><span class="headingEndMark"> — </span>By 2015, the millennium development goal target of reversing TB incidence was achieved, with TB incidence falling globally for several years beginning around 2006, at a rate of 1.5 to 2 percent per year [<a href="#rid3">3</a>]. Moreover, the global TB mortality rate has fallen by 45 percent since 1990. However, if the slow rate of decline in TB incidence and mortality is not accelerated, TB will continue to be a substantial source of global morbidity and mortality for decades.</p><p>An estimated 30 percent of patients with TB disease remain undiagnosed. Nearly half of the "missing cases" occur in Indonesia, India, and China [<a href="#rid3">3</a>]. Data on treatment success rates follow similar geographic patterns, although these rates reflect only the proportion of patients who received treatment. It is sometimes uncertain whether these patients completed an effective treatment course. The western Pacific and eastern Mediterranean have the greatest success (91 to 92 percent); other regions have fared less well (75 to 82 percent). Success is limited in part by the high prevalence of HIV infection in Africa and drug resistance in Eastern Europe.</p><p>Most patients who are coinfected with TB and HIV are not recognized to be coinfected. For example, the worldwide percentage of patients with TB disease who underwent subsequent HIV testing improved only marginally (from 1 to 55 percent) during the time period 2002 to 2015.</p><p>Detection and treatment of MDR-TB are also inadequate. The WHO estimates that only a third of patients with MDR-TB were identified in 2021 and, of those, only 60 percent were successfully treated.</p><p class="headingAnchor" id="H6"><span class="h1">IN THE UNITED STATES</span><span class="headingEndMark"> — </span>Following a marked decline in the incidence of TB in the United States over several decades, the incidence rose in the period 1985 to 1992 [<a href="#rid16">16,17</a>]. Since 1992, there has been a substantial decline in the rate of TB; in 2014, it fell to a historic low of 2.9 per 100,000  (<a class="graphic graphic_figure graphicRef66025" href="/d/graphic/66025.html" rel="external">figure 2</a>). In 2022, it was at 2.5 per 100,000, a 5 percent increase from 2021 that may partially be attributable to the coronavirus disease (COVID-19) pandemic [<a href="#rid18">18</a>].</p><p>A majority of TB cases in the United States now occurs in foreign-born individuals emigrating from countries with high rates of endemic TB (73 percent of United States TB cases in 2022; the case rate in this group is 12.8 per 100,000) [<a href="#rid18">18</a>]. Of these cases, 16.5 percent occurred in individuals residing in the United States for &lt;1 year [<a href="#rid19">19</a>]. Restriction fragment length polymorphism (RFLP) analysis has demonstrated that most of these cases are due to reactivation of latent infection rather than transmission within communities [<a href="#rid20">20-25</a>]. Therefore, screening for and treatment of latent infection is an important prevention tool among foreign-born individuals.</p><p>Increased travel and immigration of individuals from countries with endemic TB are certain to bring new challenges to TB control. In 2000, it was estimated that 11 million individuals with latent TB (with capacity for future reactivation) reside in the United States [<a href="#rid26">26</a>]. The countries accounting for the majority of cases of TB in foreign-born persons in the United States are Mexico, the Philippines, Vietnam, India, China, and the Dominican Republic and Haiti. The states accounting for the greatest number of United States cases are California, New York, New Jersey, Texas, and Florida  (<a class="graphic graphic_figure graphicRef66885" href="/d/graphic/66885.html" rel="external">figure 3</a>) [<a href="#rid27">27,28</a>].</p><p>According to data from the United States National TB Surveillance System, greater than 84.7 percent of TB patients in the United States received HIV testing in 2022; of these, 4.7 percent were HIV infected [<a href="#rid18">18</a>]. HIV infection rates in TB patients are highest among people who inject drugs, people who are homeless, correctional facility inmates, and people with an alcohol use disorder (35, 22, 16, and 15 percent, respectively) [<a href="#rid29">29</a>].</p><p>TB in the United States has been shown to be seasonal, with a peak in the spring and a trough in the fall [<a href="#rid30">30</a>]. Latitude-dependent factors, including reduced winter sunlight and its potential effect on vitamin D levels, do not appear to contribute significantly to seasonality in the United States. Instead, seasonality appears to be greater among clustered cases and children, groups in whom disease likely reflects recent transmission of TB. Therefore, TB disease resulting from recent infection with early progression to disease appears to be more influenced by season than disease that results from activation of latent TB.</p><p class="headingAnchor" id="H7"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors for TB may be divided as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired immunity (host factors)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased exposure to infectious persons (environmental factors)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Host factors</span><span class="headingEndMark"> — </span>Categories of host factors are outlined in the following sections. The relative risk for selected risk factors is outlined below. The relative importance of different risk factors varies with prevalence of exposure across regions.</p><p class="headingAnchor" id="H1843191119"><span class="h3">Immunosuppression</span></p><p class="headingAnchor" id="H3132577512"><span class="h4">HIV infection</span><span class="headingEndMark"> — </span>Among HIV-infected individuals, the risk of acquiring TB is 9 to 16 times that of HIV-uninfected individuals [<a href="#rid31">31,32</a>]. The magnitude of risk is likely variable depending on the degree of HIV-induced immunosuppression [<a href="#rid27">27,33-35</a>].</p><p>The WHO estimated 10.6 million new TB cases in 2021, 6.7 percent of whom were people living with HIV [<a href="#rid4">4</a>]. The 2020 estimated incidence of TB by country and the prevalence of HIV in TB cases by country are summarized in the figures  (<a class="graphic graphic_figure graphicRef55097" href="/d/graphic/55097.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef98732" href="/d/graphic/98732.html" rel="external">figure 4</a>).</p><p>The global incidence of new TB cases among HIV-infected patients has declined since 2000, largely due to increasing access to antiretroviral therapy (ART)  (<a class="graphic graphic_figure graphicRef141625" href="/d/graphic/141625.html" rel="external">figure 5</a>).</p><p>A large proportion of the global burden of HIV-associated TB occurs in sub-Saharan Africa, with 74 percent of new cases of TB and 79 percent of deaths. The burden is particularly high in southern Africa, where some countries have annual TB incidence rates exceeding 1000 per 100,000 population.</p><p>Dual infection with HIV and TB leads to reciprocal interactions that have significant clinical impact, as discussed in the following sections.</p><p class="headingAnchor" id="H1945117429"><span class="h5">Effect of HIV on TB</span><span class="headingEndMark"> — </span>The risk of TB doubles within the first year of HIV seroconversion due to rapid depletion of TB-specific T helper cells [<a href="#rid36">36-38</a>]. Thereafter, the risk of TB progressively increases with declining immunity [<a href="#rid32">32,39-41</a>].</p><p>HIV-infected individuals appear to be more likely to acquire <em>M. tuberculosis</em> if exposed [<a href="#rid42">42,43</a>], and they are also at increased risk of developing active TB from reactivated latent infection [<a href="#rid41">41</a>]. In addition, HIV infection is a risk factor for accelerated progression of TB following exposure; in one study, the duration of TB disease prior to diagnosis was estimated to be three times shorter in HIV-infected patients than in HIV-uninfected patients [<a href="#rid44">44</a>]. HIV-infected persons starting ART are at particularly high risk for being diagnosed with TB disease; this is likely "unmasking" of clinically unrecognized disease [<a href="#rid45">45-47</a>].</p><p>The risk of disease and death from TB is substantially increased among HIV-infected individuals due to reactivation from pre-existing latent TB and in the setting of new TB infection with rapid progression of disease [<a href="#rid48">48-52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In low-incidence settings with low transmission risk, the rate of progression to active TB disease is 3 to 13 percent per year [<a href="#rid32">32,41</a>]; the higher risk occurs in patients with CD4 &lt;200 [<a href="#rid41">41</a>]. In two nosocomial TB outbreaks described in the United States and Italy, the risk of TB disease following exposure was 37 to 50 percent in individuals with HIV infection and no known prior exposure [<a href="#rid53">53,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In high-incidence settings with high transmission risk, the likelihood of progression to active TB disease is generally higher. In tuberculin skin test-positive HIV-infected individuals, the incidence of active TB ranges from 3 to 21 per 100 person-years [<a href="#rid55">55</a>]. In a cohort of individuals with advanced HIV infection in South Africa, the incidence of active TB was 68 per 100 person-years, likely the result of new infection and prevalent latent TB infection [<a href="#rid39">39</a>].</p><p></p><p>The risk of TB transmission from HIV-infected patients with TB is lower than the risk of TB transmission from HIV-uninfected patients with TB; this is because of the shorter disease duration as well as the higher proportion of sputum smear-negative TB seen with HIV infection [<a href="#rid56">56</a>]. In addition, advanced HIV-related immunosuppression (CD4 ≤250 cells/mm<sup>3</sup>) has also been associated with reduced likelihood of TB transmission [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H4149910537"><span class="h5">Effect of TB on HIV</span><span class="headingEndMark"> — </span>TB appears to increase the risk of progression to acquired immunodeficiency syndrome (AIDS) or death [<a href="#rid58">58,59</a>]. The acceleration of HIV diseases by TB may occur via one or more of the following mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>TB infection is associated with significant increases in HIV viremia [<a href="#rid60">60</a>]. HIV viremia usually declines after initiation of successful TB treatment [<a href="#rid61">61</a>]; however, persistently high levels of viremia have been observed in some cases despite initiation of effective antituberculous therapy [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Generalized immune activation, due to TB infection, may increase the proportion of CD4 cells that are preferential targets for HIV [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased expression of the HIV co-receptors CCR5 and CXCR4 occurs in HIV-infected patients with TB coinfection [<a href="#rid62">62</a>].</p><p></p><p class="headingAnchor" id="H3523650055"><span class="h5">Impact of ART on TB incidence</span><span class="headingEndMark"> — </span>Despite unmasking of TB seen soon after initiation of antiretroviral therapy (ART), the long-term risk of TB decreases with initiation of ART [<a href="#rid65">65-75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including more than 800 HIV-infected patients with baseline CD4 count between 200 and 350 cells/mm<sup>3</sup> randomized to "early ART" (within two weeks of enrollment) or "deferred ART" (ART initiated based on time to onset of clinical AIDS or attainment of a CD4 cell count &lt;200 cells/mm<sup>3</sup>), patients who received early ART had lower rate of incident TB than those who received deferred ART (18 versus 36 cases; hazard ratio [HR] 2.0, 95% CI 1.2-3.6) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational study in South Africa including more than 1500 patients on ART, TB incidence in patients with CD4 count &lt;100 and CD4 count &gt;700 cells/mm<sup>3</sup> was 26 and 3 per 100 person-years, respectively [<a href="#rid72">72</a>]. The TB incidence among patients with CD4 &gt;700 cells/mm<sup>3</sup> was 4.4-fold higher than the incidence in HIV-uninfected individuals from the same community; however, this is likely an overestimate as TB case ascertainment was high in this cohort.</p><p></p><p class="headingAnchor" id="H907342199"><span class="h5">Risk for relapse and recurrence</span><span class="headingEndMark"> — </span>HIV-infected patients have an increased risk of recurrent TB after successful therapy, usually due to exogenous reinfection [<a href="#rid76">76-78</a>]. In one study including more than 580 culture-positive episodes of TB, recurrent TB was more common among HIV-infected patients than in HIV-uninfected patients; reinfection accounted for 12 of 23 in HIV-infected individuals and 1 of 16 recurrences among HIV-uninfected patients [<a href="#rid79">79</a>].</p><p>Patients with an initial episode of TB represent a susceptible population at high risk for a second infection with a new strain. In one study including 342 HIV-infected and 321 HIV-uninfected miners in South Africa, rates of recurrent TB (more than two years after the initial episode) were 24 and 4 percent, respectively [<a href="#rid77">77</a>]. Rates of recurrent TB were higher than rates of initial infection.</p><p>Low CD4 lymphocyte count is a key risk factor for relapse [<a href="#rid80">80,81</a>]. Among HIV-uninfected patients, cavitation and positive culture after two months of treatment are predictors of subsequent relapse among HIV-uninfected patients [<a href="#rid82">82</a>]; these may also be predictors among HIV-infected patients but have been less well studied.</p><p class="headingAnchor" id="H385072788"><span class="h4">Other forms of immunosuppression</span></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids – Patients receiving a daily dose of ≥15 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (or its equivalent) for ≥1 month are at increased risk for TB [<a href="#rid83">83</a>]. A case-control study in the United Kingdom including more than 16 million person-years of TB risk demonstrated that patients with TB were 4.9 times more likely to have been using glucocorticoids than those without TB [<a href="#rid84">84</a>]. A meta-analysis also suggests that inhaled corticosteroids increase the risk of TB [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes – Patients with diabetes are at increased risk for developing active TB and experience worse treatment outcomes [<a href="#rid86">86-89</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor necrosis factor (TNF) inhibitors – TNF-alpha inhibitors (used in the treatment of rheumatic diseases and inflammatory bowel disease) impair host resistance to TB. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transplant – Renal, cardiac, liver, and allogeneic stem cell transplants are all associated with increased risk for TB [<a href="#rid90">90-93</a>]. The risk in allogeneic stem cell transplants is less than in solid organ transplant patients; there does not appear to be an increased risk of TB in autologous stem cell transplant patients.</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Substance abuse</span><span class="headingEndMark"> — </span>Substance abuse is the most commonly reported behavioral risk factor among patients with TB in the United States [<a href="#rid94">94</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Drug use – The epidemiologic factors associated with injection and non-injection drug use (eg, homelessness, incarceration) contribute to the high prevalence of TB among drug users [<a href="#rid41">41,95-99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco – Cigarette smoking confers a relative risk of about 1.5 to 2 for the development of TB [<a href="#rid100">100-104</a>]. Smoking has been found to be associated with both risk of relapse of TB and TB mortality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol – The risk of active TB is substantially elevated in individuals who consume more than 40 g alcohol per day [<a href="#rid105">105</a>]. This may be due to the effect of alcohol and alcohol-related conditions on the immune system.</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Nutritional status</span><span class="headingEndMark"> — </span>Malnutrition is an important risk factor for TB; however, the relationship between impaired immunity due to malnutrition and risk of acquiring TB has not been well characterized [<a href="#rid106">106-110</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Underweight – Persons who are underweight (body mass index of &lt;18.5) have increased risk for TB by a factor of 2.6 (1.2 to 4.8) [<a href="#rid106">106,107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin D – Vitamin D plays an important role in macrophage activation and restriction of mycobacterial growth, and diminished serum vitamin D levels appear to increase risk for TB infection [<a href="#rid111">111-118</a>]. Among African immigrants in Australia, for example, individuals with latent or active TB were observed to have substantially lower serum vitamin D levels than those without TB [<a href="#rid115">115</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron status – Iron is an important growth factor for <em>M. tuberculosis</em> in macrophages and appears to play an important role in host susceptibility to TB infection [<a href="#rid119">119</a>].</p><p></p><p>Issues related to nutrition supplementation for prevention of incident TB are discussed separately. (See  <a class="medical medical_review" href="/d/html/8022.html" rel="external">"Prevention of tuberculosis: BCG immunization and nutritional supplementation", section on 'Nutritional supplementation'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Systemic diseases</span><span class="headingEndMark"> — </span>The diseases discussed in this section have been noted to confer some degree of increased risk for TB reactivation. However, in some cases, it can be difficult to discern the relative risk of systemic diseases for development of active TB, since many studies were performed in areas where the prevalence of TB is relatively low.</p><p class="bulletIndent1"><span class="glyph">●</span>Silicosis – The risk of TB is increased among miners with silicosis. The mechanism is not fully understood but may be related to impairment of pulmonary macrophage function by silica crystals. The relative risk depends on the severity of the silicosis and has been estimated at 1.4 to 2.9 [<a href="#rid120">120-122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy – The risk of TB is increased in patients with hematologic malignancies and head and neck cancer [<a href="#rid123">123</a>]. In a 25-year review of cancer patients in the United States, the rate of TB among patients with hematologic neoplasms was &gt;200 cases per 100,000 persons, or about 40 times the rate among the general population. Among patients with head and neck cancer, the rate was &gt;100 cases per 100,000 persons. It is important to note that these studies were performed in areas where the prevalence of TB is relatively low.</p><p></p><p class="bulletIndent1">Patients with solid tumors other than head and neck cancer do not have an increased risk for TB; among these individuals, the rate paralleled that of the general population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes – The risk of developing TB increases with increasing diabetes severity [<a href="#rid124">124,125</a>]. A case-control study of 5290 patients demonstrated that poorly controlled diabetes confers a 2.9-fold increase in the risk of developing pulmonary TB; the risk associated with well-controlled diabetes was minimal [<a href="#rid34">34</a>]. The mechanism by which diabetes confers an altered immune response to <em>M. tuberculosis</em> is not fully understood but may be related in part to altered cytokine expression [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal disease – The risk of TB among patients with chronic renal disease risk is 6.9 to 52.5 times that of individuals without renal disease [<a href="#rid127">127,128</a>]. Uremia causes reduced cellular immunity. Other factors that may diminish immunity in the setting of renal failure include malnutrition, vitamin D deficiency, and hyperparathyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastric surgery – Gastric resection for peptic ulcer disease has been described as a risk factor for TB (relative risk 1.7 to 2.0) [<a href="#rid129">129,130</a>]. Although this procedure is no longer performed routinely, gastric bypass is a similar procedure that may confer similar risk [<a href="#rid131">131</a>]. The mechanism is not understood but may be related to loss of gastric acidity; however, the risk of TB among persons with gastric achlorhydria has not been studied.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Celiac disease – Celiac disease (autoimmune inflammation of the small intestine) is a risk factor for TB; the mechanism is not fully understood but may be related to malabsorption [<a href="#rid132">132</a>]. In a study of two national registries, the risk of TB was significantly higher among 14,335 individuals with a prior diagnosis of celiac disease than among the 69,888 matched controls (hazard ratio 3.74).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis – Two studies have demonstrated that cirrhosis is a risk factor for TB; one study evaluated persons largely affected by alcohol-associated cirrhosis [<a href="#rid133">133</a>] and a second in persons with cirrhosis largely resulting from chronic infectious hepatitis [<a href="#rid134">134</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>COPD – Chronic obstructive pulmonary disease (COPD) is also a predisposing factor for TB. In two studies, COPD was associated with increased risk for TB of 2.2 (1.2 to 4.1) and 2.5 (2.2 to 2.8) [<a href="#rid135">135,136</a>]. However, some of this increased risk may be attributable to smoking or use of corticosteroids among persons with COPD.</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Age and sex</span></p><p class="bulletIndent1"><span class="glyph">●</span>Age – In resource-limited settings, TB rates are highest among young adults, reflecting primary transmission in this age group. In the United States and other developed countries, the rate of TB among older adults is higher than among younger adults and children, reflecting reactivation disease, possibly attributable to impaired immunity with aging [<a href="#rid137">137</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex – Among HIV-uninfected individuals, the rate of TB is higher among males than females, beginning in the young adult years and persisting throughout life. This observation is thought to reflect more frequent TB exposure in the community among men than women [<a href="#rid138">138</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Social and environmental factors</span></p><p class="headingAnchor" id="H15"><span class="h3">Household contacts</span><span class="headingEndMark"> — </span>Close household contact with an individual with smear-positive pulmonary TB is the most important risk factor for TB [<a href="#rid139">139,140</a>]. In a study of TB contact investigation including 1080 smear-positive patients and their 6225 close contacts, 36 percent of contacts had positive tuberculin skin tests [<a href="#rid141">141</a>]; this compares with an expected skin test–positive rate of only 2.9 percent in the general population [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Birth in a TB-endemic area</span><span class="headingEndMark"> — </span>The fraction of TB cases in the United States ascribed to foreign-born individuals increased from 22 to 58 percent between 1986 and 2007 and has continued to climb since then; by 2022, it was 73 percent  (<a class="graphic graphic_figure graphicRef66025" href="/d/graphic/66025.html" rel="external">figure 2</a>) [<a href="#rid18">18,28,142</a>]. The risk of TB is highest in the first year after immigration but remains higher than the United States–born population for up to 20 years after arrival [<a href="#rid19">19,143</a>]. Seven countries account for the majority of cases of TB in foreign-born persons in the United States: Mexico, the Philippines, Vietnam, India, China, and the Dominican Republic and Haiti [<a href="#rid19">19,142,144</a>].</p><p>Overseas screening for TB among United States–bound immigrants and refugees is a high-yield intervention for identifying TB and could reduce the number of TB cases among foreign-born persons in the United States [<a href="#rid145">145,146</a>]. Between 1999 and 2005, the prevalence of smear-negative and latent TB cases among immigrants was 961 and 837 cases per 100,000, respectively; the prevalence of these entities among refugees was 1036 and 2838 per 100,000, respectively. Active pulmonary TB and latent TB were diagnosed in the United States in 7 and 1.6 percent of those with overseas diagnoses, respectively. The risk for reactivation of latent TB is highest just after entry into the United States but remains elevated for many years after arrival [<a href="#rid147">147,148</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Community settings</span><span class="headingEndMark"> — </span>In places where contact with infectious individuals may occur, risk for acquiring TB infection is increased [<a href="#rid149">149</a>]. Crowding and poor ventilation can increase the risk of transmission in such settings [<a href="#rid150">150-157</a>]. Those at risk for increased exposure include residents and employees of congregate settings such as hospitals, correctional facilities, nursing homes, and homeless shelters. Among 1289 inmates incarcerated in 16 Maryland prisons in 1997, the incidence of tuberculin skin conversion was 6.3 infections per 100 person-years [<a href="#rid150">150</a>]. (See  <a class="medical medical_review" href="/d/html/8000.html" rel="external">"Tuberculosis transmission and control in health care settings"</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Socioeconomic status</span><span class="headingEndMark"> — </span>TB has traditionally been associated with low socioeconomic status, which also may be associated with crowding, poor nutrition, poor access to medical care, public assistance, unemployment, and low education [<a href="#rid158">158</a>].</p><p class="headingAnchor" id="H19"><span class="h3">Minority groups</span><span class="headingEndMark"> — </span>TB disease rates in the United States vary among demographic groups. In 2020, the disease incidence among non-United States-born White, Hispanic, Black, and Asian individuals was 2.8, 8.0, 15.3, and 21.7 per 100,000, respectively [<a href="#rid159">159</a>]. </p><p class="headingAnchor" id="H370252090"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15485.html" rel="external">"Patient education: Tuberculosis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4012.html" rel="external">"Patient education: Tuberculosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>More than 1.7 billion people are estimated to be infected with tuberculosis (TB). The global incidence of TB disease peaked around 2003 and appears to be declining slowly. The World Health Organization (WHO) estimated that the incidence of active disease in 2021 was 10.6 million new cases, an incidence rate of 136 per 100,000 persons. (See <a class="local">'Global burden'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poverty, HIV, and drug resistance fan the flames of the TB epidemic. Worldwide, about 95 percent of TB cases occur in resource-limited countries. Among all new TB cases in 2021, 6.7 percent were estimated to be HIV infected; 74 percent of these cases occur in Africa. In 2021, there were an estimated 440,000 cases of multidrug-resistant (MDR-) TB. (See <a class="local">'Global burden'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV is a major driver of the global TB epidemic; HIV-infected persons are at increased risk of acquiring infection, at increased risk of progressing from infection to disease, and at increased risk of death, compared with HIV-uninfected persons. These risks can be greatly reduced by administration of antiretroviral therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2015, the WHO announced the “End TB” strategy, with new milestones and targets for 2025 and 2035 that could lead to substantial reductions in the global TB burden  (<a class="graphic graphic_table graphicRef99089" href="/d/graphic/99089.html" rel="external">table 2</a>). (See <a class="local">'WHO "End TB" strategy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Socioeconomic development and access and quality of health services appear to be at least as important as any specific TB control measure. Risk factors for TB may be divided into issues related to host immunity (eg, immunologic defects that lead to increased susceptibility to infection) and issues related to environmental exposure to infection (eg, risk of exposure to a case of infectious TB). (See <a class="local">'Epidemiology and socioeconomic factors'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A majority of TB cases in the United States occurs in foreign-born individuals emigrating from countries with high rates of endemic TB. (See <a class="local">'In the United States'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum--review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis 2010; 4:e744.</a></li><li><a class="nounderline abstract_t">Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med 2016; 13:e1002152.</a></li><li class="breakAll">World Health Organization. Global tuberculosis report 2020. https://www.who.int/publications/i/item/9789240013131 (Accessed on April 05, 2021).</li><li class="breakAll">World Health Organization. Global Tuberculosis Report 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 (Accessed on May 04, 2023).</li><li><a class="nounderline abstract_t">Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367:926.</a></li><li><a class="nounderline abstract_t">Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373:1861.</a></li><li><a class="nounderline abstract_t">Dye C, Lönnroth K, Jaramillo E, et al. Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ 2009; 87:683.</a></li><li><a class="nounderline abstract_t">Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol Rev 2001; 23:288.</a></li><li><a class="nounderline abstract_t">Lönnroth K, Raviglione M. The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Trans R Soc Trop Med Hyg 2016; 110:148.</a></li><li><a class="nounderline abstract_t">Fukunaga R, Glaziou P, Harris JB, et al. Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2019. MMWR Morb Mortal Wkly Rep 2021; 70:427.</a></li><li><a class="nounderline abstract_t">Golub JE, Mohan CI, Comstock GW, Chaisson RE. Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis 2005; 9:1183.</a></li><li><a class="nounderline abstract_t">Corbett EL, Bandason T, Duong T, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet 2010; 376:1244.</a></li><li><a class="nounderline abstract_t">Verver S, Warren RM, Munch Z, et al. Proportion of tuberculosis transmission that takes place in households in a high-incidence area. Lancet 2004; 363:212.</a></li><li><a class="nounderline abstract_t">Marks GB, Nguyen NV, Nguyen PTB, et al. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. N Engl J Med 2019; 381:1347.</a></li><li class="breakAll">World Health Organization. Latent TB Infection: Updated and consolidated guidelines for programmatic management, 2018. https://apps.who.int/iris/handle/10665/260233 (Accessed on March 06, 2018).</li><li><a class="nounderline abstract_t">Burzynski J, Schluger NW. The epidemiology of tuberculosis in the United States. Semin Respir Crit Care Med 2008; 29:492.</a></li><li><a class="nounderline abstract_t">Khan K, Wang J, Hu W, et al. Tuberculosis infection in the United States: national trends over three decades. Am J Respir Crit Care Med 2008; 177:455.</a></li><li><a class="nounderline abstract_t">Schildknecht KR, Pratt RH, Feng PI, et al. Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2023; 72:297.</a></li><li><a class="nounderline abstract_t">Cain KP, Haley CA, Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med 2007; 175:75.</a></li><li><a class="nounderline abstract_t">Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002; 346:1453.</a></li><li><a class="nounderline abstract_t">Chin DP, DeRiemer K, Small PM, et al. Differences in contributing factors to tuberculosis incidence in U.S. -born and foreign-born persons. Am J Respir Crit Care Med 1998; 158:1797.</a></li><li><a class="nounderline abstract_t">Tornieporth NG, Ptachewich Y, Poltoratskaia N, et al. Tuberculosis among foreign-born persons in New York City, 1992-1994: implications for tuberculosis control. Int J Tuberc Lung Dis 1997; 1:528.</a></li><li><a class="nounderline abstract_t">Borgdorff MW, Behr MA, Nagelkerke NJ, et al. Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity. Int J Tuberc Lung Dis 2000; 4:287.</a></li><li><a class="nounderline abstract_t">Jasmer RM, Ponce de Leon A, Hopewell PC, et al. Tuberculosis in Mexican-born persons in San Francisco: reactivation, acquired infection and transmission. Int J Tuberc Lung Dis 1997; 1:536.</a></li><li><a class="nounderline abstract_t">Walter ND, Jasmer RM, Grinsdale J, et al. Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective. Clin Infect Dis 2008; 46:103.</a></li><li><a class="nounderline abstract_t">Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008; 177:348.</a></li><li class="breakAll">Horsburgh CR, Moore M, Castro KG. Epidemiology of tuberculosis in the United States. In: Tuberculosis, 2nd ed, Rom WN, Garay SM (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.31.</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Trends in tuberculosis--United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:249.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Reported HIV status of tuberculosis patients--United States, 1993-2005. MMWR Morb Mortal Wkly Rep 2007; 56:1103.</a></li><li><a class="nounderline abstract_t">Willis MD, Winston CA, Heilig CM, et al. Seasonality of tuberculosis in the United States, 1993-2008. Clin Infect Dis 2012; 54:1553.</a></li><li><a class="nounderline abstract_t">Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993; 7:1345.</a></li><li><a class="nounderline abstract_t">Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274:143.</a></li><li><a class="nounderline abstract_t">Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009.</a></li><li><a class="nounderline abstract_t">Pablos-Méndez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87:574.</a></li><li><a class="nounderline abstract_t">Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423.</a></li><li><a class="nounderline abstract_t">Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191:150.</a></li><li><a class="nounderline abstract_t">Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008; 198:1590.</a></li><li><a class="nounderline abstract_t">Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.</a></li><li><a class="nounderline abstract_t">Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75.</a></li><li><a class="nounderline abstract_t">Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464.</a></li><li><a class="nounderline abstract_t">Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.</a></li><li><a class="nounderline abstract_t">Jones-López EC, Acuña-Villaorduña C, Ssebidandi M, et al. Cough Aerosols of Mycobacterium tuberculosis in the Prediction of Incident Tuberculosis Disease in Household Contacts. Clin Infect Dis 2016; 63:10.</a></li><li><a class="nounderline abstract_t">Whalen CC, Chiunda A, Zalwango S, et al. Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. Am J Trop Med Hyg 2006; 75:55.</a></li><li><a class="nounderline abstract_t">Corbett EL, Charalambous S, Moloi VM, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004; 170:673.</a></li><li><a class="nounderline abstract_t">Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177:680.</a></li><li><a class="nounderline abstract_t">Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175:87.</a></li><li><a class="nounderline abstract_t">Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605.</a></li><li class="breakAll">World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing: 2006. World Health Organization, Geneva 2010 (WHO/HTM/TB/2010.362).</li><li><a class="nounderline abstract_t">Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic--when will we act? Lancet 2010; 375:1906.</a></li><li><a class="nounderline abstract_t">Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060.</a></li><li><a class="nounderline abstract_t">van der Sande MA, Schim van der Loeff MF, Bennett RC, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004; 18:1933.</a></li><li><a class="nounderline abstract_t">Whalen CC, Zalwango S, Chiunda A, et al. Secondary attack rate of tuberculosis in urban households in Kampala, Uganda. PLoS One 2011; 6:e16137.</a></li><li><a class="nounderline abstract_t">Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231.</a></li><li><a class="nounderline abstract_t">Di Perri G, Cruciani M, Danzi MC, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989; 2:1502.</a></li><li><a class="nounderline abstract_t">Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; :CD000171.</a></li><li><a class="nounderline abstract_t">Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353:444.</a></li><li><a class="nounderline abstract_t">Huang CC, Tchetgen ET, Becerra MC, et al. The effect of HIV-related immunosuppression on the risk of tuberculosis transmission to household contacts. Clin Infect Dis 2014; 58:765.</a></li><li><a class="nounderline abstract_t">López-Gatell H, Cole SR, Hessol NA, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol 2007; 165:1134.</a></li><li><a class="nounderline abstract_t">Badri M, Ehrlich R, Wood R, et al. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001; 5:225.</a></li><li><a class="nounderline abstract_t">Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001; 123:233.</a></li><li><a class="nounderline abstract_t">Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157:1271.</a></li><li><a class="nounderline abstract_t">Wolday D, Tegbaru B, Kassu A, et al. Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients. J Acquir Immune Defic Syndr 2005; 39:265.</a></li><li><a class="nounderline abstract_t">Wolday D, Hailu B, Girma M, et al. Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive ethiopians. Int J Tuberc Lung Dis 2003; 7:110.</a></li><li><a class="nounderline abstract_t">Vanham G, Edmonds K, Qing L, et al. Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clin Exp Immunol 1996; 103:30.</a></li><li><a class="nounderline abstract_t">Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059.</a></li><li><a class="nounderline abstract_t">Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441.</a></li><li><a class="nounderline abstract_t">Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19:1113.</a></li><li><a class="nounderline abstract_t">Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14:1985.</a></li><li><a class="nounderline abstract_t">Girardi E, Sabin CA, d'Arminio Monforte A, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41:1772.</a></li><li><a class="nounderline abstract_t">Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109.</a></li><li><a class="nounderline abstract_t">Keiper MD, Beumont M, Elshami A, et al. CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis. A study of the relationship between these factors in patients with human immunodeficiency virus infection. Chest 1995; 107:74.</a></li><li><a class="nounderline abstract_t">Gupta A, Wood R, Kaplan R, et al. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One 2012; 7:e34156.</a></li><li><a class="nounderline abstract_t">del Amo J, Moreno S, Bucher HC, et al. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012; 54:1364.</a></li><li><a class="nounderline abstract_t">Lawn SD, Wood R, De Cock KM, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10:489.</a></li><li><a class="nounderline abstract_t">Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257.</a></li><li><a class="nounderline abstract_t">Lahey T, Mackenzie T, Arbeit RD, et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis 2013; 56:151.</a></li><li><a class="nounderline abstract_t">Glynn JR, Murray J, Bester A, et al. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J Infect Dis 2010; 201:704.</a></li><li><a class="nounderline abstract_t">Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis 2010; 201:691.</a></li><li><a class="nounderline abstract_t">Crampin AC, Mwaungulu JN, Mwaungulu FD, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010; 24:417.</a></li><li><a class="nounderline abstract_t">Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731.</a></li><li><a class="nounderline abstract_t">Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175:1199.</a></li><li><a class="nounderline abstract_t">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a class="nounderline abstract_t">Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.</a></li><li><a class="nounderline abstract_t">Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55:19.</a></li><li><a class="nounderline abstract_t">Dong YH, Chang CH, Lin Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest 2014; 145:1286.</a></li><li><a class="nounderline abstract_t">Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5:e152.</a></li><li><a class="nounderline abstract_t">Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011; 9:81.</a></li><li><a class="nounderline abstract_t">Ugarte-Gil C, Alisjahbana B, Ronacher K, et al. Diabetes Mellitus Among Pulmonary Tuberculosis Patients From 4 Tuberculosis-endemic Countries: The TANDEM Study. Clin Infect Dis 2020; 70:780.</a></li><li><a class="nounderline abstract_t">Eckold C, Kumar V, Weiner J, et al. Impact of Intermediate Hyperglycemia and Diabetes on Immune Dysfunction in Tuberculosis. Clin Infect Dis 2021; 72:69.</a></li><li><a class="nounderline abstract_t">Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis 1983; 5:216.</a></li><li><a class="nounderline abstract_t">Muñoz P, Palomo J, Muñoz R, et al. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995; 21:398.</a></li><li><a class="nounderline abstract_t">Meyers BR, Halpern M, Sheiner P, et al. Tuberculosis in liver transplant patients. Transplantation 1994; 58:301.</a></li><li><a class="nounderline abstract_t">Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect 2006; 62:421.</a></li><li><a class="nounderline abstract_t">Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med 2009; 169:189.</a></li><li><a class="nounderline abstract_t">Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009; 48:72.</a></li><li><a class="nounderline abstract_t">Durante AJ, Selwyn PA, O'Connor PG. Risk factors for and knowledge of Mycobacterium tuberculosis infection among drug users in substance abuse treatment. Addiction 1998; 93:1393.</a></li><li><a class="nounderline abstract_t">Daley CL, Hahn JA, Moss AR, et al. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Respir Crit Care Med 1998; 157:19.</a></li><li><a class="nounderline abstract_t">Pevzner ES, Robison S, Donovan J, et al. Tuberculosis transmission and use of methamphetamines in Snohomish County, WA, 1991-2006. Am J Public Health 2010; 100:2481.</a></li><li><a class="nounderline abstract_t">Gardy JL, Johnston JC, Ho Sui SJ, et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 2011; 364:730.</a></li><li><a class="nounderline abstract_t">Bates MN, Khalakdina A, Pai M, et al. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med 2007; 167:335.</a></li><li><a class="nounderline abstract_t">Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009; 180:475.</a></li><li><a class="nounderline abstract_t">Rao VG, Bhat J, Yadav R, et al. Tobacco smoking: a major risk factor for pulmonary tuberculosis--evidence from a cross-sectional study in central India. Trans R Soc Trop Med Hyg 2014; 108:474.</a></li><li><a class="nounderline abstract_t">Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis 2007; 11:1049.</a></li><li><a class="nounderline abstract_t">Leung CC, Yew WW, Chan CK, et al. Smoking adversely affects treatment response, outcome and relapse in tuberculosis. Eur Respir J 2015; 45:738.</a></li><li><a class="nounderline abstract_t">Lönnroth K, Williams BG, Stadlin S, et al. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health 2008; 8:289.</a></li><li><a class="nounderline abstract_t">PALMER CE, JABLON S, EDWARDS PQ. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am Rev Tuberc 1957; 76:517.</a></li><li><a class="nounderline abstract_t">Edwards LB, Livesay VT, Acquaviva FA, Palmer CE. Height, weight, tuberculous infection, and tuberculous disease. Arch Environ Health 1971; 22:106.</a></li><li><a class="nounderline abstract_t">Tverdal A. Body mass index and incidence of tuberculosis. Eur J Respir Dis 1986; 69:355.</a></li><li><a class="nounderline abstract_t">Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med 2007; 167:1297.</a></li><li><a class="nounderline abstract_t">Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004; 8:286.</a></li><li><a class="nounderline abstract_t">Chandra G, Selvaraj P, Jawahar MS, et al. Effect of vitamin D3 on phagocytic potential of macrophages with live Mycobacterium tuberculosis and lymphoproliferative response in pulmonary tuberculosis. J Clin Immunol 2004; 24:249.</a></li><li><a class="nounderline abstract_t">Sita-Lumsden A, Lapthorn G, Swaminathan R, Milburn HJ. Reactivation of tuberculosis and vitamin D deficiency: the contribution of diet and exposure to sunlight. Thorax 2007; 62:1003.</a></li><li><a class="nounderline abstract_t">Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355:618.</a></li><li><a class="nounderline abstract_t">Ustianowski A, Shaffer R, Collin S, et al. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. J Infect 2005; 50:432.</a></li><li><a class="nounderline abstract_t">Gibney KB, MacGregor L, Leder K, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis 2008; 46:443.</a></li><li><a class="nounderline abstract_t">Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 2011; 108:19013.</a></li><li><a class="nounderline abstract_t">Wallis RS, Zumla A. Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review. Open Forum Infect Dis 2016.</a></li><li><a class="nounderline abstract_t">Aibana O, Huang CC, Aboud S, et al. Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis. PLoS Med 2019; 16:e1002907.</a></li><li><a class="nounderline abstract_t">Boelaert JR, Vandecasteele SJ, Appelberg R, Gordeuk VR. The effect of the host's iron status on tuberculosis. J Infect Dis 2007; 195:1745.</a></li><li><a class="nounderline abstract_t">Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 1994; 150:1460.</a></li><li><a class="nounderline abstract_t">Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000; 14:2759.</a></li><li><a class="nounderline abstract_t">Kleinschmidt I, Churchyard G. Variation in incidences of tuberculosis in subgroups of South African gold miners. Occup Environ Med 1997; 54:636.</a></li><li><a class="nounderline abstract_t">Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006; 42:1592.</a></li><li><a class="nounderline abstract_t">Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012; 54:818.</a></li><li><a class="nounderline abstract_t">Yoon YS, Jung JW, Jeon EJ, et al. The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study. Thorax 2017; 72:263.</a></li><li><a class="nounderline abstract_t">Restrepo BI, Fisher-Hoch SP, Pino PA, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 2008; 47:634.</a></li><li><a class="nounderline abstract_t">Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16:38.</a></li><li><a class="nounderline abstract_t">Pien FD, Younoszai BG, Pien BC. Mycobacterial infections in patients with chronic renal disease. Infect Dis Clin North Am 2001; 15:851.</a></li><li><a class="nounderline abstract_t">THORN PA, BROOKES VS, WATERHOUSE JA. Peptic ulcer, partial gastrectomy, and pulmonary tuberculosis. Br Med J 1956; 1:603.</a></li><li><a class="nounderline abstract_t">Steiger Z, Nickel WO, Shannon GJ, et al. Pulmonary tuberculosis after gastric resection. Am J Surg 1976; 131:668.</a></li><li><a class="nounderline abstract_t">Bruce RM, Wise L. Tuberculosis after jejunoileal bypass for obesity. Ann Intern Med 1977; 87:574.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Wahlstrom J, Grunewald J, et al. Coeliac disease and risk of tuberculosis: a population based cohort study. Thorax 2007; 62:23.</a></li><li><a class="nounderline abstract_t">Thulstrup AM, Mølle I, Svendsen N, Sørensen HT. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect 2000; 124:221.</a></li><li><a class="nounderline abstract_t">Lin YT, Wu PH, Lin CY, et al. Cirrhosis as a risk factor for tuberculosis infection--a nationwide longitudinal study in Taiwan. Am J Epidemiol 2014; 180:103.</a></li><li><a class="nounderline abstract_t">Inghammar M, Ekbom A, Engström G, et al. COPD and the risk of tuberculosis--a population-based cohort study. PLoS One 2010; 5:e10138.</a></li><li><a class="nounderline abstract_t">Lee CH, Lee MC, Shu CC, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 2013; 13:194.</a></li><li><a class="nounderline abstract_t">Hochberg NS, Horsburgh CR Jr. Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis 2013; 56:1240.</a></li><li><a class="nounderline abstract_t">Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis 1982; 125:8.</a></li><li class="breakAll">WHO. The Stop TB Strategy: Building on and Enhancing DOTS to meet the TB-Related Millennium Develpment Goals https://apps.who.int/iris/handle/10665/69241 (Accessed on December 08, 2011).</li><li><a class="nounderline abstract_t">Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377:147.</a></li><li><a class="nounderline abstract_t">Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162:2033.</a></li><li><a class="nounderline abstract_t">Zuber PL, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997; 278:304.</a></li><li><a class="nounderline abstract_t">Tsang CA, Langer AJ, Navin TR, Armstrong LR. Tuberculosis Among Foreign-Born Persons Diagnosed ≥10 Years After Arrival in the United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2017; 66:295.</a></li><li><a class="nounderline abstract_t">McKenna MT, McCray E, Jones JL, et al. The fall after the rise: Tuberculosis in the United States, 1991 through 1994. Am J Public Health 1998; 88:1059.</a></li><li><a class="nounderline abstract_t">Liu Y, Weinberg MS, Ortega LS, et al. Overseas screening for tuberculosis in U.S.-bound immigrants and refugees. N Engl J Med 2009; 360:2406.</a></li><li><a class="nounderline abstract_t">Barnett ED, Weld LH, McCarthy AE, et al. Spectrum of illness in international migrants seen at GeoSentinel clinics in 1997-2009, part 1: US-bound migrants evaluated by comprehensive protocol-based health assessment. Clin Infect Dis 2013; 56:913.</a></li><li><a class="nounderline abstract_t">Walter ND, Painter J, Parker M, et al. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med 2014; 189:88.</a></li><li><a class="nounderline abstract_t">Aldridge RW, Zenner D, White PJ, et al. Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519 955 migrants screened before entry to England, Wales, and Northern Ireland. Lancet 2016; 388:2510.</a></li><li><a class="nounderline abstract_t">Ribeiro FK, Pan W, Bertolde A, et al. Genotypic and Spatial Analysis of Mycobacterium tuberculosis Transmission in a High-Incidence Urban Setting. Clin Infect Dis 2015; 61:758.</a></li><li><a class="nounderline abstract_t">MacIntyre CR, Kendig N, Kummer L, et al. Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. Clin Infect Dis 1997; 24:1060.</a></li><li><a class="nounderline abstract_t">Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985; 312:1483.</a></li><li><a class="nounderline abstract_t">Schieffelbein CW Jr, Snider DE Jr. Tuberculosis control among homeless populations. Arch Intern Med 1988; 148:1843.</a></li><li><a class="nounderline abstract_t">Pablos-Mendez A, Raviglione MC, Battan R, Ramos-Zuniga R. Drug resistant tuberculosis among the homeless in New York City. N Y State J Med 1990; 90:351.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Drug-resistant tuberculosis among the homeless--Boston. MMWR Morb Mortal Wkly Rep 1985; 34:429.</a></li><li><a class="nounderline abstract_t">Nolan CM, Elarth AM, Barr H, et al. An outbreak of tuberculosis in a shelter for homeless men. A description of its evolution and control. Am Rev Respir Dis 1991; 143:257.</a></li><li><a class="nounderline abstract_t">Nardell E, McInnis B, Thomas B, Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986; 315:1570.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Tuberculosis outbreak associated with a homeless shelter - Kane County, Illinois, 2007-2011. MMWR Morb Mortal Wkly Rep 2012; 61:186.</a></li><li><a class="nounderline abstract_t">Cantwell MF, McKenna MT, McCray E, Onorato IM. Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998; 157:1016.</a></li><li><a class="nounderline abstract_t">Deutsch-Feldman M, Pratt RH, Price SF, et al. Tuberculosis - United States, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:409.</a></li></ol></div><div id="topicVersionRevision">Topic 8018 Version 75.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927191" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mycobacterium africanum--review of an important cause of human tuberculosis in West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27780211" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27780211" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27780211" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16546541" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19375159" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19784448" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in tuberculosis incidence and their determinants in 134 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12192738" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884490" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33764960" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16333924" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Active case finding of tuberculosis: historical perspective and future prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923715" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14738796" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Proportion of tuberculosis transmission that takes place in households in a high-incidence area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31577876" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Community-wide Screening for Tuberculosis in a High-Prevalence Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31577876" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Community-wide Screening for Tuberculosis in a High-Prevalence Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18810683" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The epidemiology of tuberculosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029790" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tuberculosis infection in the United States: national trends over three decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36952282" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tuberculosis - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17038659" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12000815" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Changes in the transmission of tuberculosis in New York City from 1990 to 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847270" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Differences in contributing factors to tuberculosis incidence in U.S. -born and foreign-born persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9487451" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tuberculosis among foreign-born persons in New York City, 1992-1994: implications for tuberculosis control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10777075" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9487452" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tuberculosis in Mexican-born persons in San Francisco: reactivation, acquired infection and transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171222" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989346" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989346" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300406" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Trends in tuberculosis--United States, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962801" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Reported HIV status of tuberculosis patients--United States, 1993-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474225" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Seasonality of tuberculosis in the United States, 1993-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8267907" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A prospective study of the risk of tuberculosis among HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7596002" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742798" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146434" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18647985" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Opportunities and challenges for HIV care in overlapping HIV and TB epidemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609223" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000013" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17115046" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Microbial translocation is a cause of systemic immune activation in chronic HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10708059" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16810113" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2915665" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025837" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cough Aerosols of Mycobacterium tuberculosis in the Prediction of Incident Tuberculosis Disease in Household Contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837709" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191919" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202347" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16973982" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868441" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868441" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488516" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The HIV-associated tuberculosis epidemic--when will we act?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15141044" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Priorities for the treatment of latent tuberculosis infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15353979" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339819" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Secondary attack rate of tuberculosis in urban households in Kampala, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1345800" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2574778" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Nosocomial epidemic of active tuberculosis among HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091503" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of latent tuberculosis infection in HIV infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989714" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24368620" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The effect of HIV-related immunosuppression on the risk of tuberculosis transmission to household contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17339383" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of tuberculosis on the survival of women infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11326821" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207653" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757635" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15980685" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588010" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive ethiopians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565282" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12086758" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17589190" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990564" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10997404" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16288403" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284460" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7813316" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis. A study of the relationship between these factors in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22479548" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460971" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610331" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647201" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972862" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20121434" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20121433" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Impact of HIV infection on the recurrence of tuberculosis in South India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042847" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14986259" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17290042" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment outcomes of patients with HIV and tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764341" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16463407" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Glucocorticoid use, other associated factors, and the risk of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504044" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18630984" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21722362" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The impact of diabetes on tuberculosis treatment outcomes: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30958536" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Diabetes Mellitus Among Pulmonary Tuberculosis Patients From 4 Tuberculosis-endemic Countries: The TANDEM Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32533832" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Impact of Intermediate Hyperglycemia and Diabetes on Immune Dysfunction in Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6342092" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562750" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Tuberculosis in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053051" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Tuberculosis in liver transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413085" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Tuberculosis in stem cell transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171816" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Tuberculosis and substance abuse in the United States, 1997-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19046064" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Tuberculosis and illicit drug use: review and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9926545" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Risk factors for and knowledge of Mycobacterium tuberculosis infection among drug users in substance abuse treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445273" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167896" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Tuberculosis transmission and use of methamphetamines in Snohomish County, WA, 1991-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21345102" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Whole-genome sequencing and social-network analysis of a tuberculosis outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325294" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542475" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24970276" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Tobacco smoking: a major risk factor for pulmonary tuberculosis--evidence from a cross-sectional study in central India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17945060" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Tobacco and tuberculosis: a qualitative systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359352" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Smoking adversely affects treatment response, outcome and relapse in tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702821" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Alcohol use as a risk factor for tuberculosis - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13470303" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4992917" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Height, weight, tuberculous infection, and tuberculous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3792471" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Body mass index and incidence of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592104" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Lower risk of tuberculosis in obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15139466" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114055" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Effect of vitamin D3 on phagocytic potential of macrophages with live Mycobacterium tuberculosis and lymphoproliferative response in pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17526677" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Reactivation of tuberculosis and vitamin D deficiency: the contribution of diet and exposure to sunlight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10696983" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15907552" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173355" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025704" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31509529" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17492589" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The effect of the host's iron status on tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7952577" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The epidemiology of tuberculosis in gold miners with silicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11125895" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423575" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Variation in incidences of tuberculosis in subgroups of South African gold miners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16652317" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The risk of tuberculosis in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238171" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553224" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18652554" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535299" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Tuberculosis and chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11570145" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Mycobacterial infections in patients with chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13293399" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Peptic ulcer, partial gastrectomy, and pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/937642" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Pulmonary tuberculosis after gastric resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/921087" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Tuberculosis after jejunoileal bypass for obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047199" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Coeliac disease and risk of tuberculosis: a population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10813146" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24829509" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Cirrhosis as a risk factor for tuberculosis infection--a nationwide longitudinal study in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20405056" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : COPD and the risk of tuberculosis--a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23631563" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362286" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Prevention of tuberculosis in older adults in the United States: obstacles and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7073104" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Epidemiology of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7073104" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Epidemiology of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145581" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112109" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Outcomes of contact investigations of infectious tuberculosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228436" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Long-term risk of tuberculosis among foreign-born persons in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28333913" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Tuberculosis Among Foreign-Born Persons Diagnosed≥10 Years After Arrival in the United States, 2010-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663154" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : The fall after the rise: Tuberculosis in the United States, 1991 through 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494216" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Overseas screening for tuberculosis in U.S.-bound immigrants and refugees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223584" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Spectrum of illness in international migrants seen at GeoSentinel clinics in 1997-2009, part 1: US-bound migrants evaluated by comprehensive protocol-based health assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24308495" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Persistent latent tuberculosis reactivation risk in United States immigrants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742165" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519 955 migrants screened before entry to England, Wales, and Northern Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25948063" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Genotypic and Spatial Analysis of Mycobacterium tuberculosis Transmission in a High-Incidence Urban Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9195058" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3990748" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3401108" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Tuberculosis control among homeless populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2117263" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Drug resistant tuberculosis among the homeless in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3925317" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Drug-resistant tuberculosis among the homeless--Boston.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1990937" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : An outbreak of tuberculosis in a shelter for homeless men. A description of its evolution and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3097543" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Exogenous reinfection with tuberculosis in a shelter for the homeless.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22437912" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Tuberculosis outbreak associated with a homeless shelter - Kane County, Illinois, 2007-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563713" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33764959" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Tuberculosis - United States, 2020.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
